Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 12, 2025

anti-mouse CD8?

RRID:AB_1125541
Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0061, RRID:AB_1125541)

Antibody Information

URL: http://antibodyregistry.org/AB_1125541

Proper Citation: (Bio X Cell Cat# BE0061, RRID:AB_1125541)

Target Antigen: CD8?

Host Organism: rat

Clonality: monoclonal

Comments: Applications: in vivo CD8+ T cell depletion

Antibody Name: anti-mouse CD8?

Description: This monoclonal targets CD8?

Target Organism: mouse

Clone ID: clone 2.43

Antibody ID: AB_1125541

Vendor: Bio X Cell

Catalog Number: BE0061

Alternative Catalog Numbers: BE0061-25MG, BP0061-100MG, BP0061-5MG, BE0061-50MG, BE0061-1MG, BP0061-50MG, BE0061-100MG, BE0061-5MG, BP0061-25MG

Record Creation Time: 20231110T031638+0000

Record Last Update: 20240725T082144+0000

Ratings and Alerts

No rating or validation information has been found for anti-mouse CD8?.

No alerts have been found for anti-mouse CD8?.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 145 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Wang T, et al. (2024) The histone lysine methyltransferase MLL1 regulates the activation and functional specialization of regulatory T cells. Cell reports, 43(5), 114222.

Delconte RB, et al. (2024) Fasting reshapes tissue-specific niches to improve NK cell-mediated anti-tumor immunity. Immunity, 57(8), 1923.

Mei Y, et al. (2024) IL-37 dampens immunosuppressive functions of MDSCs via metabolic reprogramming in the tumor microenvironment. Cell reports, 43(3), 113835.

Porier DL, et al. (2024) Humoral and T-cell-mediated responses to an insect-specific flavivirus-based Zika virus vaccine candidate. PLoS pathogens, 20(10), e1012566.

Ran L, et al. (2024) The transcription regulator ID3 maintains tumor-specific memory CD8+ T cells in draining lymph nodes during tumorigenesis. Cell reports, 43(9), 114690.

Liu W, et al. (2024) SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activation. Cell metabolism, 36(10), 2245.

Jacobs C, et al. (2024) HSF1 Inhibits Antitumor Immune Activity in Breast Cancer by Suppressing CCL5 to Block CD8+ T-cell Recruitment. Cancer research, 84(2), 276.

Delaunay T, et al. (2024) Exogenous non-coding dsDNA-dependent trans-activation of phagocytes augments anti-tumor immunity. Cell reports. Medicine, 5(5), 101528.

Liu J, et al. (2024) QDPR deficiency drives immune suppression in pancreatic cancer. Cell metabolism, 36(5), 984.

Jiang H, et al. (2024) Oncolytic cytomegaloviruses expressing EGFR-retargeted fusogenic

glycoprotein complex and drug-controllable interleukin 12. Cell reports. Medicine, 101874.

Hu C, et al. (2024) Tumor-secreted FGF21 acts as an immune suppressor by rewiring cholesterol metabolism of CD8+T cells. Cell metabolism, 36(3), 630.

Geng ZH, et al. (2024) YY1: a key regulator inhibits gastric cancer ferroptosis and mediating apatinib-resistance. Cancer cell international, 24(1), 71.

Colucci M, et al. (2024) Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells. Cancer cell.

Sun X, et al. (2024) Deletion of the mRNA endonuclease Regnase-1 promotes NK cell anti-tumor activity via OCT2-dependent transcription of Ifng. Immunity, 57(6), 1360.

Jackson CM, et al. (2024) The cytokine Meteorin-like inhibits anti-tumor CD8+ T cell responses by disrupting mitochondrial function. Immunity, 57(8), 1864.

Liu K, et al. (2024) Thymosin ?1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy. Cell reports. Medicine, 5(10), 101751.

Li Y, et al. (2024) Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer. Cell reports. Medicine, 5(2), 101397.

van Elsas MJ, et al. (2024) Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer cell, 42(6), 1032.

Lim RJ, et al. (2024) CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer. Cell reports. Medicine, 5(4), 101479.

Xue G, et al. (2024) Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy. Cancer cell.